proton pump inhibitors (PPIs) and hearing loss

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

Since the introduction of omeprazole in 1989, proton pump inhibitors (PPIs) have steadily become the mainstay in treatment of acid-related disorders (1)

  • Pavaci et al undertook an analysis of the audiological characteristics and comorbidity in patients with chronic tinnitus and found that:
    • proton pump inhibitors and levothyroxine showed a statistically significant correlation with the presence of chronic tinnitus (2)

  • a study (3) (n=1,379) found proton pump inhibitor (PPI) use was associated with increased risk of sensorineural hearing loss (SNHL) or tinnitus (OR: 1.61, 95% CI: 1.30-1.99) with higher risk for current or recent use of PPI and high average daily dose

Reference:

  • Strand DS, Kim D, Peura DA. 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017;11(1):27-37. doi:10.5009/gnl15502
  • Pavaci S, Tortorella F, Fioretti AB, et al. Analysis of the audiological characteristics and comorbidity in patients with chronic tinnitus. Audiol Res. 2019;9(2):231. Published 2019 Dec 19. doi:10.4081/audiores.2019.231
  • tudy (n=1,379) found proton pump inhibitor (PPI) use was associated with increased risk of sensorineural hearing loss (SNHL) or tinnitus (OR: 1.61, 95% CI: 1.30-1.99) with higher risk for current or recent use of PPI and high average daily dose

Last edited 01/2022 and last reviewed 01/2022

Links: